D-CURA 25000 IU price in UAE

Overview

Welcome to Dwaey, specifically on D-CURA 25000 IU Oral Solution page.
This medicine contains an important and useful components, as it consists of Cholecalciferol.
D-CURA 25000 IU is available in the market in concentration 25000 IU/ml and in the form of Oral Solution.

SAUDI ARABIAN JAPANESE PHARMACEUTICAL CO. LTD is the producer of D-CURA 25000 IU and it is imported from SAUDI ARABIA, The most popular alternatives of D-CURA 25000 IU are listed downward .

Mode Of Action

Lamsoprazole: Proton pump inhibitor; binds to H+/K+-exchanging ATPase (proton pump) in gastric parietal cells resulting in blocking acid secretion. Amoxicillin: Inhibits bacterial cell wall synthesis by binding to one or more penicillin binding proteins that in turn inhibit the final transpeptidation step of peptoglycan synthesis in cell wall biosynthesis. Clarithromycin: Inhibits protein synthesis by binding to 50S ribosomal subunit causing antibacterial activity.

Indication

H. pylori infection
Peptic ulcer disease
Duodenal Ulcer

Precaution

Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients on penicillin therapy, including amoxicillin. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin hypersensitivity and/or a history of sensitivity to multiple allergens. Lactation: Not recommended

Side Effects

>10% Clarithromycin GI effects
general (13%) 1-10% Clarithromycin Headache (6%)
Rash (children 3%)
Abdominal pain (adults 2%
children 3%)
Abnormal taste (adults 3-7%)
Diarrhea (3-6%)
Dyspepsia (2%)
Heartburn (adults 2%)
GI intolerance (oral-dose related)
Nausea (adults 3-6%)
Vomiting (adults 1%; children 6%)
Decreased WBC
elevated BUN (4%)
elevated PT (1%) Lansoprazole Fatigue (< 3%)
Headache (2.5-4.7%)
Abdominal pain (1.8%)
Diarrhea (8%)
Nausea (3.7%) <1% Clarithromycin QT prolongation
Anxiety
dizziness
hallucinations
manic behavior
neuromuscular blockade
psychosis
seizures
Anorexia
glossitis
pancreatitis
AST increased
bilirubin increased
elevated LFTs
hepatic dysfunction
hepatitis
increased alkaline phosphate
jaundice
Hypoglycemia
leukopenia
neutropenia
thrombocytopenia
Increased serum creatinine
Dyspnea
Anaphylaxis
C Diff colitis
Stevens-Johnson syndrome Frequency Not Defined Amoxicillin Headache
Rash
Diarrhea
nausea
vomiting
Anemia
AST/ALT elevation
Acute exanthematous pustulosis
Exfoliative dermatitis Seizure
Insomnia
Hemorrhagic colitis
Toxic epidermal necrolysis
Urticaria
Stevens-Johnson syndrome
Anaphylaxis
Candidiasis (mucocutaneous)
pseudomembranous colitis
serum sickness Clarithromycin Torsade de pointes (rare)
Allergic reactions: urticaria & skin eruptions
leukocytoclastic vasculitis
toxic epidermal necrolysis
pruritus
rash Transient CNS effects: psychosis
anxiety
behavioral changes
confusional states
depersonalization
disorientation
hallucinations
insomnia
nightmares
tinnitus
tremor
and vertigo
Hepatic failure
Stomatitis
Acute renal failure
Reversible hearing loss (hypoacusis)

Contra indication

Contraindicated in patients with known severe hypersensitivity to any component. Clarithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin. Clarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes. A history of severe hypersensitivity reactions (e.g., anaphylaxis or Stevens-Johnson syndrome) to amoxicillin or other beta-lactam antibiotics (e.g., penicillins and cephalosporins) is a contraindication. Clarithromycin is contraindicated in patients with a known hypersensitivity to clarithromycin, erythromycin, or any of the macrolide antibiotics. Clarithromycin is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of clarithromycin. Clarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes. Amoxicillin/clarithromycin/lansoprazole is not recommended in patients with CrCl less than 30 mL/min.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Interaction

Amoxicillin: May reduce the efficacy of OC. May increase the effect of anticoagulants. Increased risk of allergic reactions w/ allopurinol. Increased and prolonged blood levels w/ probenecid. Chloramphenicol, macrolides, sulfonamides and tetracyclines may interfere w/ the bactericidal effect of amoxicillin. Clarithromycin: Serious adverse reactions have been reported in patients taking Clarithromycin concomitantly with CYP3A4 substrates. These include colchicine toxicity with colchicine; rhabdomyolysis with simvastatin, lovastatin, and atorvastatin; and hypotension and acute kidney injury with calcium channel blockers metabolized by CYP3A4 (e.g., verapamil, amlodipine, diltiazem, nifedipine). Most reports of acute kidney injury with calcium channel blockers metabolized by CYP3A4 involved elderly patients 65 years of age or older. Lansoprazole: Increased risk of hypomagnesaemia w/ diuretics and digoxin. May decrease plasma concentration of erlotinib, dasatinib and lapatinib. May decrease the bioavailability of itraconazole and ketoconazole. May increase plasma concentration of cilostazol and methotrexate. Reduced bioavailability w/ antacids and sucralfate. Potentially Fatal: May decrease serum levels and pharmacological effects of rilpivirine and atazanavir.